India's largest pharmaceutical acquisition strengthens Sun Pharma's global reach and positions the company among the world's leading biosimilars players.
Sun Pharmaceutical Industries is advancing plans for its proposed US$11.75 billion acquisition of Organon, a transaction that could significantly alter the competitive landscape for biosimilars and established medicines while creating one of the world's largest pharmaceutical companies by revenue. The deal, announced in April 2026, remains on track for completion in early 2027, subject to regulatory and shareholder approvals.
The acquisition represents the largest overseas pharmaceutical transaction undertaken by an Indian drugmaker and marks a strategic shift for Sun Pharma as it expands beyond its traditional strengths in generics and specialty medicines. Upon completion, the combined company is expected to generate approximately US$12.4 billion in annual revenue, placing it among the top 25 pharmaceutical companies globally, and top three company in global women’s health.
Since announcing the transaction, Sun Pharma has continued preparations for integration and financing of the acquisition, which will be funded through a combination of cash reserves and committed bank financing. Analysts have largely viewed the deal as a transformative move that broadens Sun Pharma's international footprint while enhancing its portfolio in women's health, established brands and biosimilars.
Strengthening biosimilars presence
For the biosimilars sector, the transaction is particularly significant. Organon markets a portfolio of biosimilars through its general medicines business and operates commercial networks across more than 140 countries. The acquisition is expected to elevate Sun Pharma into the ranks of the world's leading biosimilars companies, with the combined entity projected to become the seventh-largest global biosimilars player.
Organon was spun off from Merck in 2021 and has built a diversified portfolio spanning women's health, biosimilars and established medicines. The company markets more than 70 products globally and maintains six manufacturing facilities across Europe and emerging markets. Its commercial presence in Brazil, Canada, China, Europe, and the US is expected to complement Sun Pharma's existing strengths in specialty medicines and branded generics.
The deal also expands Sun Pharma's access to therapeutic areas that have become increasingly important growth drivers across the pharmaceutical industry, including women's health and specialty care. Company executives have said the combination will create a stronger platform for future growth while diversifying revenue sources geographically and therapeutically.
Consolidation trend gains momentum
The acquisition underscores the growing importance of scale in the biosimilars market, where commercial reach, manufacturing capabilities and market access have become increasingly critical to long-term success. While many recent pharmaceutical transactions have focused on innovative drug pipelines, Sun Pharma's pursuit of Organon reflects the strategic value of established commercial infrastructure and global distribution networks.
For biosimilars manufacturers, the transaction highlights a broader industry trend toward consolidation as companies seek greater scale to compete across multiple markets. If completed as planned, the combined organization would have a presence in approximately 150 countries, creating a larger platform from which to expand biosimilars offerings and compete with established global players.
Related articles
Organon–Henlius partnership: biosimilars for women’s health
Sun Pharma and Dr Reddy’s generics progress in EU and US
Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.
Copyright – Unless otherwise stated all contents of this website are © 2026 Pro Pharma Communications International. All Rights Reserved.
0
Post your comment